These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24165098)

  • 21. Docking field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase.
    Fan N; Zhang S; Sheng T; Zhao L; Liu Z; Liu J; Wang X
    Chem Biol Drug Des; 2018 Feb; 91(2):398-407. PubMed ID: 28816417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
    Chen W; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Jiang X; Liu X
    Bioorg Med Chem; 2013 Nov; 21(22):7091-100. PubMed ID: 24119448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sporolides A and B: structurally unprecedented halogenated macrolides from the marine actinomycete Salinispora tropica.
    Buchanan GO; Williams PG; Feling RH; Kauffman CA; Jensen PR; Fenical W
    Org Lett; 2005 Jun; 7(13):2731-4. PubMed ID: 15957933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase.
    Gupta P; Kumar R; Garg P; Singh IP
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
    Wu HQ; Yan ZH; Chen WX; He QQ; Chen FE; De Clercq E; Balzarini J; Daelemans D; Pannecouque C
    Bioorg Med Chem; 2013 Nov; 21(21):6477-83. PubMed ID: 24055077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization.
    Grohmann D; Corradi V; Elbasyouny M; Baude A; Horenkamp F; Laufer SD; Manetti F; Botta M; Restle T
    Chembiochem; 2008 Apr; 9(6):916-22. PubMed ID: 18318036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
    Rai D; Chen W; Tian Y; Chen X; Zhan P; De Clercq E; Pannecouque C; Balzarini J; Liu X
    Bioorg Med Chem; 2013 Dec; 21(23):7398-405. PubMed ID: 24134904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Ma XD; Zhang X; Dai HF; Yang SQ; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE
    Bioorg Med Chem; 2011 Aug; 19(15):4601-7. PubMed ID: 21719299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Murugesan V; Tiwari VS; Saxena R; Tripathi R; Paranjape R; Kulkarni S; Makwana N; Suryawanshi R; Katti SB
    Bioorg Med Chem; 2011 Nov; 19(22):6919-26. PubMed ID: 21982685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
    Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
    SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
    Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors.
    Ma XD; Yang SQ; Gu SX; He QQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    ChemMedChem; 2011 Dec; 6(12):2225-32. PubMed ID: 21990112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining docking, molecular dynamics and the linear interaction energy method to predict binding modes and affinities for non-nucleoside inhibitors to HIV-1 reverse transcriptase.
    Carlsson J; Boukharta L; Aqvist J
    J Med Chem; 2008 May; 51(9):2648-56. PubMed ID: 18410085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
    Zhou Z; Madrid M; Madura JD
    Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
    Rodríguez-Barrios F; Balzarini J; Gago F
    J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based pharmacophore identification of new chemical scaffolds as non-nucleoside reverse transcriptase inhibitors.
    Barreca ML; De Luca L; Iraci N; Rao A; Ferro S; Maga G; Chimirri A
    J Chem Inf Model; 2007; 47(2):557-62. PubMed ID: 17274611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
    Zhan P; Li X; Li Z; Chen X; Tian Y; Chen W; Liu X; Pannecouque C; De Clercq E
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7155-62. PubMed ID: 23084898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors.
    Tremblay M; Bethell RC; Cordingley MG; DeRoy P; Duan J; Duplessis M; Edwards PJ; Faucher AM; Halmos T; James CA; Kuhn C; Lacoste JÉ; Lamorte L; LaPlante SR; Malenfant E; Minville J; Morency L; Morin S; Rajotte D; Salois P; Simoneau B; Tremblay S; Sturino CF
    Bioorg Med Chem Lett; 2013 May; 23(9):2775-80. PubMed ID: 23511023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study.
    Annan A; Raiss N; Lemrabet S; Elomari N; Elmir EH; Filali-Maltouf A; Medraoui L; Oumzil H
    Int J Immunopathol Pharmacol; 2024; 38():3946320241231465. PubMed ID: 38296818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.